There were 3 events of acute pancreatitis in the semaglutide 0.5 mg group and one event of chronic pancreatitis in the semaglutide 1.0 mg group
Disclosure of interest: Juan Alberto Aguilera Aguilera: nothing to disclose E-Posters - RISK FACTORS - PRIMARY AND SECONDAR PREVENTION 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.01 - PREVENTION P2569 - ESOC25-2431 BOTULINUM TOXIN TYPE A FOR LOWER LIMB SPASTICITY IN POST-STROKE PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS Ibrahim Serag 1 1 Faculty of Medicine, Mansoura University, Mansoura, Egypt Background and Aims: Lower limb spasticity is a disabling post-stroke complication that impairs mobility, gait, and independence, increasing the risk of falls
NJ Bio can design and select the right linker for your ADCs
Sim R, Hernndez C
Most-engaged members lost 25.2% more weight at week 40 and persisted 2.2x longer on medication program than least-engaged members using the Noom app, demonstrating the benefits of combining GLP-1 medication with Nooms GLP-1 Companion behavior-change program PRINCETON, N.J., February 4, 2026 Noom, the leading behavior change company, today shared new real-world findings from tens of thousands of members, showing a clear relationship: members who engage more with Nooms leading GLP-1 Companion app tend to lose more weight and stay on a medication program longer
The aetiology of cardiac complications in CKD is multifactorial
